Related Experiment Video

Updated: Mar 14, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K

Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine

M Zaiou1, H El Amri2

  • 1Faculté de Pharmacie, Université de Lorraine, Nancy, France.

Clinical Genetics
|October 8, 2016
PubMed

Insights

Genetic factors significantly contribute to cardiovascular disease (CVD) risk and drug response. Understanding these genetic variations can improve CVD diagnosis and personalized treatment strategies.

Area of Science:

  • Genetics and Genomics
  • Cardiovascular Medicine
  • Personalized Medicine

Background:

  • Cardiovascular disease (CVD) remains a leading global cause of mortality, with complex etiological factors.
  • Genetic predisposition is increasingly recognized as a crucial determinant in CVD development and progression.
  • Current understanding of the genetic underpinnings of CVD requires further elucidation to improve patient outcomes.

Purpose of the Study:

  • To review the scientific advancements in understanding the genetic and genomic basis of CVD.
  • To highlight the development and potential clinical utility of genetic biomarkers for CVD.
  • To discuss the limitations and future directions for translating genetic findings into clinical practice.

Main Methods:

  • Review of high-throughput genetics and genomics studies.
  • Analysis of genome-wide association studies (GWAS) and other genomic approaches.
  • Synthesis of evidence on genetic variations influencing CVD and drug responses.

Main Results:

  • Numerous genetic variations associated with CVD have been identified using advanced genomic technologies.
  • Genetic defects can impact CVD development and individual responses to cardiovascular medications (e.g., clopidogrel, aspirin, warfarin, statins).
  • Validated genetic markers hold promise for enhanced diagnostic accuracy and personalized treatment strategies.

Conclusions:

  • Genetic insights offer significant potential for personalized diagnostics and pharmacogenetics in CVD management.
  • Further research is needed to elucidate pathological mechanisms and overcome limitations in translating genetic discoveries into clinical benefits.
  • Integrating genetic information into clinical practice could revolutionize CVD prevention and treatment through personalized medicine.

Keywords:
Genome Wide Association Studiesbiomarkerscardiovascular diseasegenetic testingpersonalized medicineprecision medicinetranslational medicine

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.3K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.1K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
110
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
87
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
70